Tivantinib and Regorafenib for the Treatment of Liver Cancer
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the use of tivantinib and regorafenib for the treatment of patients with liver cancer.
Clinical Pearls
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the use of tivantinib and regorafenib for the treatment of patients with liver cancer.
- Tivantinib is in phase III development for liver cancer
- A phase II study comparing tivantinib to placebo showed no dramatic benefit in all-comers
- An analysis showed high MET expression was associated with worse prognosis, and high MET patients saw benefit from tivantinib versus low MET
- Regorafenib has shown activity in colorectal cancer and GIST
- A phase II study of regorafenib demonstrated provocative survival data for patients who have progressed on sorafenib
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
